Russell Ouellette
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Russell Ouellette has a total of 360 co-authors. Here are the top co-authors by number of shared publications:
- Tobias Granberg
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
26 shared publications - Constantina Andrada Treaba
Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital , Charlestown, MA 02129
10 shared publications Caterina Mainero
Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, MA, USA
9 shared publications- Caterina Mainero
Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, 149 13th St, Charlestown, MA 02129
9 shared publications Elena Herranz
Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital , Charlestown, MA 02129
9 shared publicationsFredrik Piehl
Center of Neurology, Academic Specialist Center, Stockholm Health Services , Stockholm 113 65
8 shared publications
Latest Publications
- Open Access
- 1 December 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (4) , e000168
Therapy Choices and Outcomes in Newly Diagnosed Multiple Sclerosis
Background and ObjectivesProspective multinational studies integrating imaging and soluble biomarkers in early multiple sclerosis (MS) are limited. The MultipleMS study compared 2-year clinical, ra...
- 1 December 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (4) , e000168
Open AccessTherapy Choices and Outcomes in Newly Diagnosed Multiple Sclerosis
Background and ObjectivesProspective multinational studies integrating imaging and soluble biomarkers in early multiple sclerosis (MS) are limited. The MultipleMS study compared 2-year clinical, ra...
- Open Access
- 20 May 2026
- Published by Elsevier in SSRN Electronic Journal
Predicting treatment responses in multiple sclerosis: a model development and geographical validation study
Background Multiple sclerosis (MS) is the most common disabling neurological disease of young adults, with many approved disease-modifying treatments (DMTs). We developed and validated a Bayesian modelling framework to predict individual-level treatment response.Methods We used two prospective cohorts of people with relapsing–remitting MS (pwMS) in the UK (training) and Sweden (external validation), with clinical and MRI data assessed within 6 months of DMT initiation, and outcomes (no-evidence-of-disease-activity (NEDA) over 2 years. Bayesian models of increasing complexity (up to 12 baseline predictors) predicted NEDA (no-evidence-of-disease-activity: absence of relapse, disability progression, and new MRI lesions) at 1 and 2 years and were externally validated. Internal performance used ELPD-LOO (expected leave-one-out log posterior density), AUROC (area-under-the-receiver-operating-characteristic curve), R² (explained variance), and calibration plots; external validation used AUROC and R².Findings The training and external cohorts comprised 1,873 and 808 pwMS, respectively, with differing baseline characteristics; NEDA occurred in 65.6% and 70.3% over 2 years. Greater model complexity improved internal NEDA prediction; the most complex model reached AUROC=0.71 (95% Bayesian Credible Interval 0.70–0.72) at year 1 and 0.66 (0.65–0.67) at year 2. External performance was modest: AUROC=0.59 (0.57–0.61) at year 1 and 0.57 (0.55–0.58) at year 2. At year 2, explained variance was low but higher for complex than DMT-only models (R²=0.08 [0.06–0.10] vs 0.03 [0.01–0.05]). Complex models showed consistent calibration across patient subgroups, and individual predictions with uncertainty were illustrated.Interpretation A Bayesian framework using routine clinical and MRI data achieved modest-to-moderate individual-level outcome prediction, but discrimination decreased on geographic validation, highlighting challenges in transporting prediction models across settings with different case-mix, monitoring and treatment practices. Further multicenter training and local model updating may improve prediction.Funding National Institute for Health and Care Research (NIHR).
- 20 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPredicting treatment responses in multiple sclerosis: a model development and geographical validation study
Background Multiple sclerosis (MS) is the most common disabling neurological disease of young adults, with many approved disease-modifying treatments (DMTs). We developed and validated a Bayesian modelling framework to predict individual-level treatment response.Methods We used two prospective cohorts of people with relapsing–remitting MS (pwMS) in the UK (training) and Sweden (external validation), with clinical and MRI data assessed within 6 months of DMT initiation, and outcomes (no-evidence-of-disease-activity (NEDA) over 2 years. Bayesian models of increasing complexity (up to 12 baseline predictors) predicted NEDA (no-evidence-of-disease-activity: absence of relapse, disability progression, and new MRI lesions) at 1 and 2 years and were externally validated. Internal performance used ELPD-LOO (expected leave-one-out log posterior density), AUROC (area-under-the-receiver-operating-characteristic curve), R² (explained variance), and calibration plots; external validation used AUROC and R².Findings The training and external cohorts comprised 1,873 and 808 pwMS, respectively, with differing baseline characteristics; NEDA occurred in 65.6% and 70.3% over 2 years. Greater model complexity improved internal NEDA prediction; the most complex model reached AUROC=0.71 (95% Bayesian Credible Interval 0.70–0.72) at year 1 and 0.66 (0.65–0.67) at year 2. External performance was modest: AUROC=0.59 (0.57–0.61) at year 1 and 0.57 (0.55–0.58) at year 2. At year 2, explained variance was low but higher for complex than DMT-only models (R²=0.08 [0.06–0.10] vs 0.03 [0.01–0.05]). Complex models showed consistent calibration across patient subgroups, and individual predictions with uncertainty were illustrated.Interpretation A Bayesian framework using routine clinical and MRI data achieved modest-to-moderate individual-level outcome prediction, but discrimination decreased on geographic validation, highlighting challenges in transporting prediction models across settings with different case-mix, monitoring and treatment practices. Further multicenter training and local model updating may improve prediction.Funding National Institute for Health and Care Research (NIHR).
- 24 April 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (6) , 598-613
Generalizable spinal cord multiple sclerosis lesion segmentation across MRI contrasts, protocols, and centers
Background/Objectives: Characterizing spinal cord multiple sclerosis (MS) lesions in MRI is critical for diagnosis, monitoring, and treatment evaluation. However, current automated approaches for lesion detection and segmentation are typically designed for specific MRI contrasts or acquisition sites, limiting their generalizability in real-world clinical settings where imaging protocols vary widely. This work proposes a robust multi-site, multi-contrast segmentation framework for spinal cord lesions. Methods: The segmentation model was trained and evaluated on a large-scale dataset comprising 4428 annotated images from 1849 persons with MS across 23 imaging centers, encompassing six MRI contrasts (T1w, T2w, T2*w, PSIR, STIR, and UNIT1) acquired at 1.5 tesla (T), 3 T, and 7 T. Results: Likert-type assessment performed by neuroradiologist ratings demonstrated superior generalization of the model compared to existing contrast-specific pipelines ( p < 0.01). Additional experiments evaluated robustness across spinal levels, acquisition resolutions, binarization thresholds, and quantitative evaluation on external labeled datasets. Conclusions: The proposed model can achieve accurate and reliable spinal cord MS lesion segmentation across heterogeneous MRI data, addressing a key barrier to clinical translation. The model is available in the Spinal Cord Toolbox v7.2 and higher. Code repository: https://github.com/ivadomed/seg-sc-ms-lesion-multicontrast
- 24 April 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (6) , 598-613
Generalizable spinal cord multiple sclerosis lesion segmentation across MRI contrasts, protocols, and centers
Background/Objectives: Characterizing spinal cord multiple sclerosis (MS) lesions in MRI is critical for diagnosis, monitoring, and treatment evaluation. However, current automated approaches for lesion detection and segmentation are typically designed for specific MRI contrasts or acquisition sites, limiting their generalizability in real-world clinical settings where imaging protocols vary widely. This work proposes a robust multi-site, multi-contrast segmentation framework for spinal cord lesions. Methods: The segmentation model was trained and evaluated on a large-scale dataset comprising 4428 annotated images from 1849 persons with MS across 23 imaging centers, encompassing six MRI contrasts (T1w, T2w, T2*w, PSIR, STIR, and UNIT1) acquired at 1.5 tesla (T), 3 T, and 7 T. Results: Likert-type assessment performed by neuroradiologist ratings demonstrated superior generalization of the model compared to existing contrast-specific pipelines ( p < 0.01). Additional experiments evaluated robustness across spinal levels, acquisition resolutions, binarization thresholds, and quantitative evaluation on external labeled datasets. Conclusions: The proposed model can achieve accurate and reliable spinal cord MS lesion segmentation across heterogeneous MRI data, addressing a key barrier to clinical translation. The model is available in the Spinal Cord Toolbox v7.2 and higher. Code repository: https://github.com/ivadomed/seg-sc-ms-lesion-multicontrast
- Open Access
- 1 January 2026
- Published by BMJ in BMJ Neurology Open
- Vol. 8 (1) , e001513
Increased susceptibility and volume reduction in deep brain nuclei in primary orthostatic tremor
Background: Primary orthostatic tremor (POT) is a rare progressive neurological disorder with a high-frequency tremor while standing. The pathophysiology remains uncertain, and imaging studies have been inconclusive. Objectives: The primary objective was to assess whether neurodegenerative changes are detectable in POT by quantitative susceptibility mapping (QSM) on brain MRI. A second objective was to explore volumetric changes in subcortical grey matter and cerebellum. Methods: In this cross-sectional study, 20 participants with POT and 14 age- and sex-matched healthy controls (HCs) were examined using a 3 T Siemens Prisma scanner with a T2*-weighted multiecho gradient-echo sequence for QSM. Regions of interest (ROIs) were automatically and manually segmented. Selected ROIs were the red nucleus, globus pallidus (GP), thalamus, caudatus, putamen, substantia nigra, dentate nucleus and inferior and superior colliculus. Results: There was a significant increase in susceptibility in the red nucleus (mean susceptibility 138.1 parts per billion (ppb) in POT and 113.3 ppb in HC, p=0.015) and GP (mean susceptibility 101.2 ppb in POT and 73.3 ppb in HC, p=0.0015) and a significantly lower volume of the GP in the POT group compared with HC (mean volume 3838 mm 3 in POT and 4062 mm 3 in HC, p=0.012). Conclusion: Increased susceptibility and decrease of volume indicate the possibility of a neurodegenerative process affecting the red nucleus and GP in POT. The red nucleus and GP are involved in motor control, and a focal dysfunction in these networks may be a part of the cause of orthostatic tremor.
- 1 January 2026
- Published by BMJ in BMJ Neurology Open
- Vol. 8 (1) , e001513
Open AccessIncreased susceptibility and volume reduction in deep brain nuclei in primary orthostatic tremor
Background: Primary orthostatic tremor (POT) is a rare progressive neurological disorder with a high-frequency tremor while standing. The pathophysiology remains uncertain, and imaging studies have been inconclusive. Objectives: The primary objective was to assess whether neurodegenerative changes are detectable in POT by quantitative susceptibility mapping (QSM) on brain MRI. A second objective was to explore volumetric changes in subcortical grey matter and cerebellum. Methods: In this cross-sectional study, 20 participants with POT and 14 age- and sex-matched healthy controls (HCs) were examined using a 3 T Siemens Prisma scanner with a T2*-weighted multiecho gradient-echo sequence for QSM. Regions of interest (ROIs) were automatically and manually segmented. Selected ROIs were the red nucleus, globus pallidus (GP), thalamus, caudatus, putamen, substantia nigra, dentate nucleus and inferior and superior colliculus. Results: There was a significant increase in susceptibility in the red nucleus (mean susceptibility 138.1 parts per billion (ppb) in POT and 113.3 ppb in HC, p=0.015) and GP (mean susceptibility 101.2 ppb in POT and 73.3 ppb in HC, p=0.0015) and a significantly lower volume of the GP in the POT group compared with HC (mean volume 3838 mm 3 in POT and 4062 mm 3 in HC, p=0.012). Conclusion: Increased susceptibility and decrease of volume indicate the possibility of a neurodegenerative process affecting the red nucleus and GP in POT. The red nucleus and GP are involved in motor control, and a focal dysfunction in these networks may be a part of the cause of orthostatic tremor.
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Neuroimaging
- Vol. 36 (1) , e70128
Rapid Estimation of Myelin for Diagnostic Imaging and Quantification of Therapy Responses in Multiple Sclerosis
Background and Purpose: Recent MRI developments have allowed for in vivo myelin imaging in clinically feasible time frames. This retrospective study aimed to evaluate the ability of the Rapid Estimation of Myelin for Diagnostic Imaging (REMyDI) technique in monitoring longitudinal myelin changes and brain atrophy in persons with multiple sclerosis (pwMS) undergoing treatment with rituximab or autologous hematopoietic stem cell transplantation (aHSCT). Methods: Between May 2017 and January 2022, 62 pwMS treated with either rituximab ( n = 25) or aHSCT ( n = 37) underwent brain MRI scans at three time points. A 3 Tesla brain MRI was performed, including 3D T1‐weighted imaging, 3D T2‐weighted fluid‐attenuated inversion recovery imaging, and 2D multi‐dynamic multi‐echo imaging for REMyDI and brain volumetrics. Longitudinal changes in imaging parameters and associations with the Expanded Disability Status Scale and Symbol Digit Modalities Test were analyzed using mixed‐effects models. Results: The rituximab group exhibited increases in whole‐brain myelin (+0.25 mL per year), cortical myelin (+0.11 mL per year), and myelin in normal‐appearing deep gray matter (NADGM) (+0.02 mL per year). In contrast, these measures were stable or declined in the aHSCT group. Brain parenchymal fraction showed a larger reduction in the rituximab group (−0.68% per year) compared to the aHSCT group (−0.24% per year). Myelin‐related imaging measures showed positive but nonsignificant associations with clinical parameters. Conclusions: REMyDI enables longitudinal assessment of myelin‐related metrics in vivo, which complements conventional brain volumetrics and is suitable for monitoring treatment responses in MS.
- 1 January 2026
- Published by Wiley in Journal of Neuroimaging
- Vol. 36 (1) , e70128
Open AccessRapid Estimation of Myelin for Diagnostic Imaging and Quantification of Therapy Responses in Multiple Sclerosis
Background and Purpose: Recent MRI developments have allowed for in vivo myelin imaging in clinically feasible time frames. This retrospective study aimed to evaluate the ability of the Rapid Estimation of Myelin for Diagnostic Imaging (REMyDI) technique in monitoring longitudinal myelin changes and brain atrophy in persons with multiple sclerosis (pwMS) undergoing treatment with rituximab or autologous hematopoietic stem cell transplantation (aHSCT). Methods: Between May 2017 and January 2022, 62 pwMS treated with either rituximab ( n = 25) or aHSCT ( n = 37) underwent brain MRI scans at three time points. A 3 Tesla brain MRI was performed, including 3D T1‐weighted imaging, 3D T2‐weighted fluid‐attenuated inversion recovery imaging, and 2D multi‐dynamic multi‐echo imaging for REMyDI and brain volumetrics. Longitudinal changes in imaging parameters and associations with the Expanded Disability Status Scale and Symbol Digit Modalities Test were analyzed using mixed‐effects models. Results: The rituximab group exhibited increases in whole‐brain myelin (+0.25 mL per year), cortical myelin (+0.11 mL per year), and myelin in normal‐appearing deep gray matter (NADGM) (+0.02 mL per year). In contrast, these measures were stable or declined in the aHSCT group. Brain parenchymal fraction showed a larger reduction in the rituximab group (−0.68% per year) compared to the aHSCT group (−0.24% per year). Myelin‐related imaging measures showed positive but nonsignificant associations with clinical parameters. Conclusions: REMyDI enables longitudinal assessment of myelin‐related metrics in vivo, which complements conventional brain volumetrics and is suitable for monitoring treatment responses in MS.
- Open Access
- 17 November 2025
- Published by Wiley in Journal of Neuroimaging
- Vol. 35 (6) , e70104
The Effect of Gadolinium on Synthetic Magnetic Resonance Quantitative Imaging
Background and Purpose: Synthetic (Sy) MRI is a clinically approved technique providing quantitative MRI measures based on T 1 ‐weighted, T 2 ‐weighted, and proton density relaxometry. MRI sequences are often acquired after contrast injection with gadolinium (Gd) to assess active lesions in persons with multiple sclerosis (PwMS), affecting relaxation time. We aimed to assess the influence of Gd on the SyMRI‐based volumetrics in PwMS. Methods: We enrolled 106 PwMS and 15 controls who performed pre‐/post‐contrast brain SyMRI on a 3T scanner. We evaluated mean change in brain parenchymal fraction (BPF), white matter (WM), grey matter (GM), myelin (Myl), non‐aqueous component (NAC), excess parenchymal water (EPW), and T 1 enhancement (T 1 E) using paired sample t ‐test for pre‐/post‐Gd volumes and independent sample t ‐test for comparison between groups. Results: The mean age was 40.9 and 39.9 years with 69% and 87% females in MS and controls, respectively. Compared to native volumetrics, Gd caused a significant observed volume increase ( p < 0.001) in BPF 1.05 ± 0.3%, WM 2.8 ± 0.99%, Myl 1.42 ± 0.39%, NAC 1.04 ± 0.23%, and EPW 0.6 ± 0.4% and decrease in GM −3.05 ± 1.34% in MS. Similar change was seen in controls: BPF 0.99 ± 0.21%, WM 2.94 ± 0.93%, Myl 1.35 ± 0.37%, NAC 0.99 ± 0.22%, EPW 0.47 ± 0.29%, and GM −2.89 ± 1.18%. The change in T 1 E was 0.05 ± 0.12% in MS ( p < 0.001) and 0.02 ± 0.25% ( p = 0.76) in controls. The number of contrast‐enhancing lesions correlated with T 1 E ( r = 0.348, p < 0.003). Conclusion: There was a consistent pattern of volume changes in PwMS and controls, except for T 1 E, where the contrast could have affected the results in PwMS. Therefore, combining pre‐ and post‐contrast metrics in longitudinal studies should be interpreted with caution.
- 17 November 2025
- Published by Wiley in Journal of Neuroimaging
- Vol. 35 (6) , e70104
Open AccessThe Effect of Gadolinium on Synthetic Magnetic Resonance Quantitative Imaging
Background and Purpose: Synthetic (Sy) MRI is a clinically approved technique providing quantitative MRI measures based on T 1 ‐weighted, T 2 ‐weighted, and proton density relaxometry. MRI sequences are often acquired after contrast injection with gadolinium (Gd) to assess active lesions in persons with multiple sclerosis (PwMS), affecting relaxation time. We aimed to assess the influence of Gd on the SyMRI‐based volumetrics in PwMS. Methods: We enrolled 106 PwMS and 15 controls who performed pre‐/post‐contrast brain SyMRI on a 3T scanner. We evaluated mean change in brain parenchymal fraction (BPF), white matter (WM), grey matter (GM), myelin (Myl), non‐aqueous component (NAC), excess parenchymal water (EPW), and T 1 enhancement (T 1 E) using paired sample t ‐test for pre‐/post‐Gd volumes and independent sample t ‐test for comparison between groups. Results: The mean age was 40.9 and 39.9 years with 69% and 87% females in MS and controls, respectively. Compared to native volumetrics, Gd caused a significant observed volume increase ( p < 0.001) in BPF 1.05 ± 0.3%, WM 2.8 ± 0.99%, Myl 1.42 ± 0.39%, NAC 1.04 ± 0.23%, and EPW 0.6 ± 0.4% and decrease in GM −3.05 ± 1.34% in MS. Similar change was seen in controls: BPF 0.99 ± 0.21%, WM 2.94 ± 0.93%, Myl 1.35 ± 0.37%, NAC 0.99 ± 0.22%, EPW 0.47 ± 0.29%, and GM −2.89 ± 1.18%. The change in T 1 E was 0.05 ± 0.12% in MS ( p < 0.001) and 0.02 ± 0.25% ( p = 0.76) in controls. The number of contrast‐enhancing lesions correlated with T 1 E ( r = 0.348, p < 0.003). Conclusion: There was a consistent pattern of volume changes in PwMS and controls, except for T 1 E, where the contrast could have affected the results in PwMS. Therefore, combining pre‐ and post‐contrast metrics in longitudinal studies should be interpreted with caution.
- Open Access
- 18 April 2025
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (3) , fcaf152
Brain age in multiple sclerosis: a study with deep learning and traditional machine learning
‘Brain age’ is a numerical estimate of the biological age of the brain and an overall effort to measure neurodegeneration, regardless of disease type. In multiple sclerosis, accelerated brain ageing has been linked to disability accrual. Artificial intelligence has emerged as a promising tool for the assessment and quantification of the impact of neurodegenerative diseases. Despite the existence of numerous AI models, there is a noticeable lack of comparative imaging data for traditional machine learning versus deep learning in conditions such as multiple sclerosis. A retrospective observational study was initiated to analyse clinical and MRI data (4584 MRIs) from various scanners in a large longitudinal cohort (n = 1516) of people with multiple sclerosis collected from two institutions (Karolinska Institute and Oslo University Hospital) using a uniform data post-processing pipeline. We conducted a comparative assessment of brain age using a deep learning simple fully convolutional network and a well-established traditional machine learning model. This study was primarily aimed to validate the deep learning brain age model in multiple sclerosis. The correlation between estimated brain age and chronological age was stronger for the deep learning estimates (r = 0.90, P < 0.001) than the traditional machine learning estimates (r = 0.75, P < 0.001). An increase in brain age was significantly associated with higher expanded disability status scale scores (traditional machine learning: t = 5.3, P < 0.001; deep learning: t = 3.7, P < 0.001) and longer disease duration (traditional machine learning: t = 6.5, P < 0.001; deep learning: t = 5.8, P < 0.001). No significant inter-model difference in clinical correlation or effect measure was found, but significant differences for traditional machine learning-derived brain age estimates were found between several scanners. Our study suggests that the deep learning-derived brain age is significantly associated with clinical disability, performed equally well to the traditional machine learning-derived brain age measures, and may counteract scanner variability.
- 18 April 2025
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (3) , fcaf152
Open AccessBrain age in multiple sclerosis: a study with deep learning and traditional machine learning
‘Brain age’ is a numerical estimate of the biological age of the brain and an overall effort to measure neurodegeneration, regardless of disease type. In multiple sclerosis, accelerated brain ageing has been linked to disability accrual. Artificial intelligence has emerged as a promising tool for the assessment and quantification of the impact of neurodegenerative diseases. Despite the existence of numerous AI models, there is a noticeable lack of comparative imaging data for traditional machine learning versus deep learning in conditions such as multiple sclerosis. A retrospective observational study was initiated to analyse clinical and MRI data (4584 MRIs) from various scanners in a large longitudinal cohort (n = 1516) of people with multiple sclerosis collected from two institutions (Karolinska Institute and Oslo University Hospital) using a uniform data post-processing pipeline. We conducted a comparative assessment of brain age using a deep learning simple fully convolutional network and a well-established traditional machine learning model. This study was primarily aimed to validate the deep learning brain age model in multiple sclerosis. The correlation between estimated brain age and chronological age was stronger for the deep learning estimates (r = 0.90, P < 0.001) than the traditional machine learning estimates (r = 0.75, P < 0.001). An increase in brain age was significantly associated with higher expanded disability status scale scores (traditional machine learning: t = 5.3, P < 0.001; deep learning: t = 3.7, P < 0.001) and longer disease duration (traditional machine learning: t = 6.5, P < 0.001; deep learning: t = 5.8, P < 0.001). No significant inter-model difference in clinical correlation or effect measure was found, but significant differences for traditional machine learning-derived brain age estimates were found between several scanners. Our study suggests that the deep learning-derived brain age is significantly associated with clinical disability, performed equally well to the traditional machine learning-derived brain age measures, and may counteract scanner variability.
- Open Access
Genetic variation in HIF1A is associated with smoldering inflammation and disease progression in Multiple Sclerosis
Background: Understanding the mechanisms underlying disease progression in Multiple Sclerosis (MS) is fundamental to pave the way to treatment advances. Smoldering demyelinating inflammation characterized by iron deposition is observed at the edges of chronic active lesions and represents a relevant substrate of disease progression in MS. However, the influence of genetic factors on these mechanisms is not known. Leveraging the importance of iron deposition in smoldering inflammation, we assessed whether variants in genes belonging to iron-related pathways affect disease progression in MS. Methods: We investigated the association between Single Nucleotide Polymorphisms (SNPs) mapping to 334 genes in iron-related pathways and the risk of disease progression, studying 2,817 MS patients from Italy (n=755) and Sweden (n=2,062), and comparing relapsing-remitting (RR-MS) with secondary progressive (SP-MS) disease course. To better understand the link of the identified variant with smoldering inflammation, we applied a multilayered approach using independent cohorts from Italy, Sweden and the United Kingdom and encompassing gene expression, PRL analysis, neurofilament levels, post-mortem spinal cord pathology and pharmacogenomics. Results: We found an association between a locus in the Hypoxia-Inducible Factor 1-alpha ( HIF1A ) gene and the odds of SP-MS transition in the Italian cohort (rs11621525; SP-MS OR 0.57, 95% CI 0.44-0.72; P=3.30×10 - 6 ), which was replicated in the Swedish dataset (rs1951795; OR 0.79, 95% CI 0.67-0.95; P=0.0079). Additional analyses showed that patients carrying the protective allele exhibited reduced HIF1A expression in the immune cells, lower PRL volume, lower plasma/cerebrospinal fluid neurofilament levels, and lower inflammation and acute axonal injury in the post-mortem spinal cord. Moreover, the variant influenced the response to dimethyl fumarate, an approved MS drug with effect on mechanisms shared with HIF1A pathway. Conclusion: A novel locus in the HIF1A gene, a crucial hub for iron-binding capacity, inflammation, and hypoxia response, is associated with the risk of disease progression in MS. Converging lines of evidence support the role of this locus in smoldering inflammation, prompting future studies to explore the potential of HIF1A as a therapeutic target in progressive MS.
Open AccessGenetic variation in HIF1A is associated with smoldering inflammation and disease progression in Multiple Sclerosis
Background: Understanding the mechanisms underlying disease progression in Multiple Sclerosis (MS) is fundamental to pave the way to treatment advances. Smoldering demyelinating inflammation characterized by iron deposition is observed at the edges of chronic active lesions and represents a relevant substrate of disease progression in MS. However, the influence of genetic factors on these mechanisms is not known. Leveraging the importance of iron deposition in smoldering inflammation, we assessed whether variants in genes belonging to iron-related pathways affect disease progression in MS. Methods: We investigated the association between Single Nucleotide Polymorphisms (SNPs) mapping to 334 genes in iron-related pathways and the risk of disease progression, studying 2,817 MS patients from Italy (n=755) and Sweden (n=2,062), and comparing relapsing-remitting (RR-MS) with secondary progressive (SP-MS) disease course. To better understand the link of the identified variant with smoldering inflammation, we applied a multilayered approach using independent cohorts from Italy, Sweden and the United Kingdom and encompassing gene expression, PRL analysis, neurofilament levels, post-mortem spinal cord pathology and pharmacogenomics. Results: We found an association between a locus in the Hypoxia-Inducible Factor 1-alpha ( HIF1A ) gene and the odds of SP-MS transition in the Italian cohort (rs11621525; SP-MS OR 0.57, 95% CI 0.44-0.72; P=3.30×10 - 6 ), which was replicated in the Swedish dataset (rs1951795; OR 0.79, 95% CI 0.67-0.95; P=0.0079). Additional analyses showed that patients carrying the protective allele exhibited reduced HIF1A expression in the immune cells, lower PRL volume, lower plasma/cerebrospinal fluid neurofilament levels, and lower inflammation and acute axonal injury in the post-mortem spinal cord. Moreover, the variant influenced the response to dimethyl fumarate, an approved MS drug with effect on mechanisms shared with HIF1A pathway. Conclusion: A novel locus in the HIF1A gene, a crucial hub for iron-binding capacity, inflammation, and hypoxia response, is associated with the risk of disease progression in MS. Converging lines of evidence support the role of this locus in smoldering inflammation, prompting future studies to explore the potential of HIF1A as a therapeutic target in progressive MS.
- 30 January 2024
- Published by Oxford University Press (OUP) in Brain
- Vol. 147 (7) , 2566-2578
Characterization of cortico-meningeal translocator protein expression in multiple sclerosis
Compartmentalized meningeal inflammation is thought to represent one of the key players in the pathogenesis of cortical demyelination in multiple sclerosis. Positron emission tomography targeting the 18 kDa mitochondrial Translocator Protein (TSPO) is a molecular-specific approach to quantify immune cell-mediated density in the cortico-meningeal tissue compartment in vivo. The aim of this study was to characterize cortical and meningeal TSPO expression in a heterogeneous cohort of multiple sclerosis cases using in vivo simultaneous MR-PET with 11C-PBR28, a second-generation TSPO radioligand, and ex vivo immunohistochemistry. Forty-nine multiple sclerosis patients (21 with secondary progressive and 28 with relapsing-remitting multiple sclerosis) with mixed or high affinity binding for 11C-PBR28 underwent 90-min 11C-PBR28 simultaneous MR-PET. Tracer binding was measured using 60-90 min normalized standardized uptake value ratio values sampled at mid-cortical depth and ∼3 mm above the pial surface. Data in multiple sclerosis patients were compared to 21 age-matched healthy controls. To characterize the nature of 11C-PBR28 PET uptake, the meningeal and cortical lesion cellular expression of TSPO was further described in post-mortem brain tissue from 20 cases with secondary progressive multiple sclerosis and five age-matched healthy donors. Relative to healthy controls, patients with multiple sclerosis exhibited abnormally increased TSPO signal in the cortex and meningeal tissue, diffusively in progressive disease and more localized in relapsing-remitting multiple sclerosis. In multiple sclerosis, increased meningeal TSPO levels were associated with increased Expanded Disability Status Scale scores (p = 0.007, by linear regression). Immunohistochemistry, validated using in-situ sequencing analysis, revealed increased TSPO expression in the meninges and adjacent subpial cortical lesions of post-mortem secondary progressive multiple sclerosis cases relative to control tissue. In these cases, increased TSPO expression was related to meningeal inflammation. Translocator Protein immunostaining was detected on meningeal major histocompatibility complex (MHC)-class II + macrophages and cortical activated MHC-class II + transmembrane protein (TMEM)119+ microglia. In vivo arterial blood data and neuropathology showed that endothelial binding did not significantly account for increased TSPO cortico-meningeal expression in multiple sclerosis. Our findings support the use of TSPO-PET in multiple sclerosis for imaging in vivo inflammation in the cortico-meningeal brain tissue compartment and provide in vivo evidence implicating meningeal inflammation in the pathogenesis of the disease.
- 30 January 2024
- Published by Oxford University Press (OUP) in Brain
- Vol. 147 (7) , 2566-2578
Characterization of cortico-meningeal translocator protein expression in multiple sclerosis
Compartmentalized meningeal inflammation is thought to represent one of the key players in the pathogenesis of cortical demyelination in multiple sclerosis. Positron emission tomography targeting the 18 kDa mitochondrial Translocator Protein (TSPO) is a molecular-specific approach to quantify immune cell-mediated density in the cortico-meningeal tissue compartment in vivo. The aim of this study was to characterize cortical and meningeal TSPO expression in a heterogeneous cohort of multiple sclerosis cases using in vivo simultaneous MR-PET with 11C-PBR28, a second-generation TSPO radioligand, and ex vivo immunohistochemistry. Forty-nine multiple sclerosis patients (21 with secondary progressive and 28 with relapsing-remitting multiple sclerosis) with mixed or high affinity binding for 11C-PBR28 underwent 90-min 11C-PBR28 simultaneous MR-PET. Tracer binding was measured using 60-90 min normalized standardized uptake value ratio values sampled at mid-cortical depth and ∼3 mm above the pial surface. Data in multiple sclerosis patients were compared to 21 age-matched healthy controls. To characterize the nature of 11C-PBR28 PET uptake, the meningeal and cortical lesion cellular expression of TSPO was further described in post-mortem brain tissue from 20 cases with secondary progressive multiple sclerosis and five age-matched healthy donors. Relative to healthy controls, patients with multiple sclerosis exhibited abnormally increased TSPO signal in the cortex and meningeal tissue, diffusively in progressive disease and more localized in relapsing-remitting multiple sclerosis. In multiple sclerosis, increased meningeal TSPO levels were associated with increased Expanded Disability Status Scale scores (p = 0.007, by linear regression). Immunohistochemistry, validated using in-situ sequencing analysis, revealed increased TSPO expression in the meninges and adjacent subpial cortical lesions of post-mortem secondary progressive multiple sclerosis cases relative to control tissue. In these cases, increased TSPO expression was related to meningeal inflammation. Translocator Protein immunostaining was detected on meningeal major histocompatibility complex (MHC)-class II + macrophages and cortical activated MHC-class II + transmembrane protein (TMEM)119+ microglia. In vivo arterial blood data and neuropathology showed that endothelial binding did not significantly account for increased TSPO cortico-meningeal expression in multiple sclerosis. Our findings support the use of TSPO-PET in multiple sclerosis for imaging in vivo inflammation in the cortico-meningeal brain tissue compartment and provide in vivo evidence implicating meningeal inflammation in the pathogenesis of the disease.
- Open Access
- 18 October 2023
- Published by Wiley in Annals of Neurology
- Vol. 94 (6) , 1080-1085
A Genetic Risk Variant for Multiple Sclerosis Severity is Associated with Brain Atrophy
The minor allele of the genetic variant rs10191329 in the DYSF‐ZNF638 locus is associated with unfavorable long‐term clinical outcomes in multiple sclerosis patients. We investigated if rs10191329 is associated with brain atrophy measured by magnetic resonance imaging in a discovery cohort of 748 and a replication cohort of 360 people with relapsing multiple sclerosis. We observed an association with 28% more brain atrophy per rs10191329*A allele. Our results encourage stratification for rs10191329 in clinical trials. Unraveling the underlying mechanisms may enhance our understanding of pathophysiology and identify treatment targets. ANN NEUROL 2023;94:1080–1085
- 18 October 2023
- Published by Wiley in Annals of Neurology
- Vol. 94 (6) , 1080-1085
Open AccessA Genetic Risk Variant for Multiple Sclerosis Severity is Associated with Brain Atrophy
The minor allele of the genetic variant rs10191329 in the DYSF‐ZNF638 locus is associated with unfavorable long‐term clinical outcomes in multiple sclerosis patients. We investigated if rs10191329 is associated with brain atrophy measured by magnetic resonance imaging in a discovery cohort of 748 and a replication cohort of 360 people with relapsing multiple sclerosis. We observed an association with 28% more brain atrophy per rs10191329*A allele. Our results encourage stratification for rs10191329 in clinical trials. Unraveling the underlying mechanisms may enhance our understanding of pathophysiology and identify treatment targets. ANN NEUROL 2023;94:1080–1085